Liquidia Corporation (LQDA)

NASDAQ: LQDA · IEX Real-Time Price · USD
11.28
+0.20 (1.81%)
Jul 22, 2024, 1:00 PM EDT - Market open
1.81%
Market Cap 852.01M
Revenue (ttm) 15.97M
Net Income (ttm) -107.69M
Shares Out 76.41M
EPS (ttm) -1.56
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 384,025
Open 11.15
Previous Close 11.08
Day's Range 11.00 - 11.39
52-Week Range 5.71 - 16.99
Beta 0.32
Analysts Strong Buy
Price Target 26.25 (+132.71%)
Earnings Date Aug 8, 2024

About LQDA

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement w... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jul 26, 2018
Employees 145
Stock Exchange NASDAQ
Ticker Symbol LQDA
Full Company Profile

Financial Performance

In 2023, Liquidia's revenue was $17.49 million, an increase of 9.75% compared to the previous year's $15.94 million. Losses were -$78.50 million, 91.4% more than in 2022.

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for LQDA stock is "Strong Buy." The 12-month stock price forecast is $26.25, which is an increase of 132.71% from the latest price.

Price Target
$26.25
(132.71% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Liquidia Announces Poster Presentations at the 7th World Symposia on Pulmonary Hypertension (WSPH)

MORRISVILLE, N.C., June 18, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today the company will present seven posters related to its product pipeline at the 7th World Symposi...

4 weeks ago - GlobeNewsWire

Liquidia Corporation Reports First Quarter 2024 Financial Results and Provides Corporate Update

MORRISVILLE, N.C., May 13, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) today reported financial results for the first quarter ended March 31, 2024.

2 months ago - GlobeNewsWire

Liquidia Announces Poster Presentation at the American Thoracic Society (ATS) 2024 International Conference on Its Open-Label Safety Study of L606 (Liposomal Treprostinil) in Patients with PAH and PH-ILD

Liquidia Corporation (NASDAQ: LQDA) announced today the company will present data at the American Thoracic Society (ATS) 2024 International Conference.

2 months ago - GlobeNewsWire

Liquidia Corporation to Present at 23rd Annual Needham Virtual Healthcare Conference

MORRISVILLE, N.C., April 02, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) announced today that Dr. Roger Jeffs, Chief Executive Officer, and Micheal Kaseta, C...

3 months ago - GlobeNewsWire

Update on Favorable Legal and Regulatory Outcomes Clearing Path for Potential FDA approval of YUTREPIA™ (treprostinil) inhalation powder

MORRISVILLE, N.C., April 01, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) announced today that on March 28, Judge Andrews of the U.S. District Court for the D...

4 months ago - GlobeNewsWire

Liquidia Corporation Reports Full Year 2023 Financial Results and Provides Corporate Update

MORRISVILLE, N.C., March 13, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) today reported financial results for the full year ended December 31, 2023. The Comp...

4 months ago - GlobeNewsWire

Liquidia Corporation to Report Full Year 2023 Financial Results on Wednesday, March 13, 2024

MORRISVILLE, N.C., March 06, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that it will report its full year 2023 financial results on Wednesday, March 13, 2024. The com...

4 months ago - GlobeNewsWire

United Therapeutics starts litigation with FDA for allowing Liquidia's drug application

United Therapeutics said on Wednesday it has commenced litigation with the U.S. FDA for allowing an application for a drug by Liquidia Corp to treat a type of blood vessel disorder.

Other symbols: UTHR
5 months ago - Reuters

Liquidia Corporation Announces Poster Presentation at the Pulmonary Vascular Research Institute 2024 Annual Congress

MORRISVILLE, N.C., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) today announced that the Company will present data from the L606 clinical program at ...

6 months ago - GlobeNewsWire

US FDA extends review for Liquidia's inhaled blood pressure drug

The U.S. Food and Drug Administration extended the review of Liquidia Corp's drug for the treatment of a progressive blood vessel disorder related to a lung condition, the company said on Thursday.

6 months ago - Reuters

Liquidia Corporation Provides Update on New Drug Application for YUTREPIA™ (treprostinil) inhalation powder

MORRISVILLE, N.C., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (the Company) (NASDAQ: LQDA) announced today that the U.S. Food and Drug Administration (FDA) provided an update on its review...

6 months ago - GlobeNewsWire

Liquidia Corporation Announces Updates to Operations Leadership

MORRISVILLE, N.C., Jan. 19, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) announced today updates and promotions to its operations leadership in advance of the...

6 months ago - GlobeNewsWire

Liquidia Corporation Files Response to United Therapeutics Lawsuit and Files Counterclaims

MORRISVILLE, N.C., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) announced today it filed its answer, affirmative defenses and a partial motion to dis...

7 months ago - GlobeNewsWire

Liquidia Provides Update on Clinical Pipeline Targeting PAH and PH-ILD

MORRISVILLE, N.C., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) provided an update today on the clinical progress of its pipeline programs to treat p...

7 months ago - GlobeNewsWire

Liquidia Corporation Announces $100 Million in New Financings

MORRISVILLE, N.C., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) announced today that the Company has entered into agreements for an additional $100 m...

7 months ago - GlobeNewsWire

Liquidia Corporation to Present at 42nd Annual J.P. Morgan Healthcare Conference

MORRISVILLE, N.C., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) announced today that Dr. Roger Jeffs, Chief Executive Officer, will present at the 42...

7 months ago - GlobeNewsWire

U.S. Federal Circuit Affirms Earlier PTAB Decision to Invalidate All Claims of United Therapeutics Patent No. 10,716,793 (‘793 Patent)

MORRISVILLE, N.C., Dec. 20, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) announced that the U.S. Court of Appeals for the Federal Circuit (Federal Circuit) to...

7 months ago - GlobeNewsWire

Liquidia Announces Pricing of Public Offering of Common Stock

MORRISVILLE, N.C., Dec. 12, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that it has priced an underwritten public offering of 3,491,620 shares of common stock at a pub...

7 months ago - GlobeNewsWire

Liquidia Corporation Reports Third Quarter 2023 Financial Results and Provides Corporate Update

MORRISVILLE, N.C., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) today reported financial results for the third quarter ended September 30, 2023. The ...

9 months ago - GlobeNewsWire

Liquidia Corporation to Report Third Quarter 2023 Financial Results on November 7, 2023

MORRISVILLE, N.C., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that it will report its third quarter 2023 financial results on Tuesday, November 7, 2023. The ...

9 months ago - GlobeNewsWire

FDA Accepts Submission to Add PH-ILD to YUTREPIA™ Label

MORRISVILLE, N.C., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (the Company) (NASDAQ: LQDA) announced today that the U.S. Food and Drug Administration (FDA) accepted for review the Company...

10 months ago - GlobeNewsWire

United Therapeutics Corporation Files Lawsuit Alleging Infringement of Tyvaso Patent Already Found to Be Invalid by U.S. Patent Office

MORRISVILLE, N.C., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company), announced today that United Therapeutics Corporation (UTHR) filed a patent infringe...

11 months ago - GlobeNewsWire

Liquidia Corporation Reports Second Quarter 2023 Financial Results and Provides Corporate Update

MORRISVILLE, N.C., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) today reported financial results for the second quarter ended June 30, 2023. The Comp...

1 year ago - GlobeNewsWire

Liquidia Corporation to Report Second Quarter 2023 Financial Results on August 10, 2023

MORRISVILLE, N.C., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that it will report its second quarter 2023 financial results on Thursday, August 10, 2023. The...

1 year ago - GlobeNewsWire

Liquidia Submits Amendment to Add PH-ILD Indication to Tentatively Approved NDA for YUTREPIA™ (treprostinil) Inhalation Powder

MORRISVILLE, N.C., July 27, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today the submission of an amendment to the tentatively approved new drug application (NDA) for YUTRE...

1 year ago - GlobeNewsWire